Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 4/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013284 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL1013283 | 1.00 | TAAR1 (0.55) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL7870676 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL9000001 | 0.98 | TAAR1 (0.53) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL4623579 | 0.83 | CA12 (0.41) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL15951403 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A2SLC7A5ESR1ESR2 | |
| SCHEMBL8855721 | 0.83 | TSHR (0.39) | TAAR1SLC6A2SLC7A5CA2 | |
| SCHEMBL2269394 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL242931 | 0.81 | CYP3A4 (0.42) | TAAR1SLC7A5CA2 | |
| SCHEMBL6670843 | 0.81 | HRH3 (0.48) | TAAR1SLC6A2ABATCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725797-B1 | STABILIZED LIQUID ENZYME COMPOSITIONS | NOVOZYMES AS (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-107090014-B | Stabilized liquid enzyme compositions | 诺维信公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-3850068-A1 | PHASE STABLE AND LOW FOAMING AQUEOUS DETERGENT COMPOSITIONS HAVING A LONG TIME ENZYME ACTIVITY | Ecolab USA Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| CN-108530322-B | Tyrosine semicarbazide hydrazone hydrochloride, its synthesis method and its use | 富乐马鸿凯（大连）医药有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3725797-A1 | STABILIZED LIQUID ENZYME COMPOSITIONS | Novozymes A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008014286-A1 | VINYL PHOSPHONATE LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-01-31 | — | — | WO | disclosed |
| US-7307148-B2 | Method for purification of albumin conjugates | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-12-11 | — | — | US | disclosed |
| US-20070280939-A1 | Prostatic Acid Phosphatase Antigens | NOTTINGHAM TRENT UNIVERSITY, THE (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070243562-A1 | Lectins for Analyzing Sugar Chains and Method of Using the Same | SUMMIT GLYCORESEARCH CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070231855-A1 | Functional molecule and manufacturing method therefor | FUJITSU LIMITED (JP) | 2007-10-04 | — | — | US | disclosed |
| US-5952189-A | SCREENING FOR ENZYME INHIBITORS FOR ANTIPROLIFERATIVE AGENTS, ANTITUMOR AGENTS, TREATMENT FOR LEUKEMIA, ACQUIRED IMMUNE DEFICIENCY SYNDROME, NERVOUS SYSTEM DISORDERS | PANORAMA RESEARCH, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| CN-1142830-A | Macrocyclic difluorostatone derivatives useful as antiviral agents | MERRELL DOW PHARMA (US) | 1997-02-12 | — | — | CN | disclosed |
| EP-0585412-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1994-03-09 | — | — | EP | disclosed |
| WO-1992018529-A1 | INCREASING BLOOD-BRAIN BARRIER PERMEABILITY WITH PERMEABILIZER PEPTIDES | ALKERMES, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070280939-A1 | Prostatic Acid Phosphatase Antigens | ACP3, KLK3, PSAP | TAAR1 3768/4885SLC6A2 3809/4885SLC7A5 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.